Systemic Mastocytosis Treatment with Midostaurin: [18F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome

Caroline Burgard; Florian Rosar; Fadi Khreish; Samer Ezziddin

doi:10.3390/diagnostics12030680

Systemic Mastocytosis Treatment with Midostaurin: [¹⁸F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome

Diagnostics (Basel). 2022 Mar 10;12(3):680. doi: 10.3390/diagnostics12030680.

Authors

Caroline Burgard¹, Florian Rosar¹, Fadi Khreish¹, Samer Ezziddin¹

Affiliation

¹ Department of Nuclear Medicine, Saarland University, 66421 Homburg, Germany.

Abstract

We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent ¹⁸F-Fluorodeoxyglucose ([¹⁸F]FDG) positron-emission tomography/computed tomography (PET/CT) pre- and post-6-month therapy with midostaurin, an established tyrosine kinase inhibitor. Post-therapeutic [¹⁸F]FDG PET/CT showed decreased multifocal tracer uptake in the known lesions in the gastrointestinal tract, which was consistent with relief of the patient's symptoms and decrease in serum tryptase level. [¹⁸F]FDG PET/CT may thus be considered a potential method for monitoring the outcome of midostaurin therapy in systemic mastocytosis.

Keywords: FDG PET/CT; midostaurin; systemic mastocytosis; therapy outcome; tyrosine kinase inhibitor.